Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, today announced the appointment of Nadir Mahmood, Ph.D., as chief executive officer and board member. Dr. Mahmood previously served as chief financial and business officer of Nkarta and brings significant leadership experience in corporate development, research and finance in the biopharmaceutical industry. Dr. Mahmood succeeds Rezo co-founder Nevan Krogan, Ph.D., who has served as interim chief executive officer and president since the company’s formation and will continue in the role of president.
“Nadir is a seasoned biotech leader and we are thrilled to welcome him to lead Rezo as our chief executive officer,” said Dr. Krogan. “This appointment underscores the strong progress we have made at Rezo in advancing our leading protein-protein interaction platform to create comprehensive, unprecedented maps of molecular disease networks to inform the development of a new wave of precision therapeutics.”